Search results :

Gemcitabine

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01BC05

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 27 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Oedema peripheral Oedema peripheral very common, 20% x x x x x x x x x x x x x x x x x x x x
Malaise Malaise 19% x x x x x x x x x x x x x x x x x x x
Discomfort Malaise 19% x x x x x x x x x x x x x x x x x x x
Feeling abnormal Malaise 19% x x x x x x x x x x x x x x x x x x x
Ill-defined disorder Malaise 19% x x x x x x x x x x x x x x x x x x x
Neutropenia Neutropenia very common, 0% - 89% x x x x x x x x x x x x x x x x x x x
Chills Shivering very common x x
Chills x x x x x x x x x x x x x x x x x
Influenza like illness Influenza-like symptoms very common x x x x x x x x x x x x x x x x x x x
Dermatitis atopic Cutaneous hypersensitivity very common x x
Oedema Oedema very rare — 13% x x x x x x x x x x x x x x x x x x x x
Lymphopenia Lymphopenia 5% - 51% x x x x
Asthenia Asthenia common, very common x x x x x x x x x x x x x x x x x x x x
Fatigue 0% - 32% x x x x x x x x x x x x x x x x
Back pain Back pain common, very common x x x
Pruritus Pruritus common, very common x x x x x x x x x x x x
Vomiting Vomiting very common, 0% - 86% x x x x x x x x x x x x x x x x x x x x
Anaemia Anaemia very common, 0% - 86% x x x x x x x x x x x x x x x x x x x x
Leukopenia Leukopenia very common, 0% - 93% x x x x x x x x x x x x x x x x
Nausea Nausea very common, 0% - 87% x x x x x x x x x x x x x x x x x x x x
Ulcer Ulcer rare, common x x x
Blood bilirubin increased Blood bilirubin increased common x x x
Insomnia Insomnia common x x x x x x x x x x x x x x x x x x
Difficulty sleeping x x
Thrombocytopenia Thrombocytopenia postmarketing — 1% - 57% x x x x x x x x x
Alanine aminotransferase increased Alanine aminotransferase increased 0% - 68% x x x x x
Aspartate aminotransferase increased Aspartate aminotransferase increased 0% - 67% x x x x x
Febrile neutropenia Febrile neutropenia common, 0% - 5% x x x x
Constipation Constipation common, 0% - 39% x x x x x x x x x x x x x x x x x x x x
Dyspnoea Dyspnoea very common, 0% - 28% x x x x x x x x x x x x x x x x x x x x
Acute dyspnea x
Hyperglycaemia Hyperglycaemia 0% - 23% x x x x x x x x x x x x x x x
Neuropathy peripheral Neuropathy peripheral 3% x x x
Neuropathy 0% - 58% x x x x x x
Myalgia Myalgia very common, 0% - 33% x x x x x x x x x x x x x x x x x x x
Musculoskeletal discomfort Myalgia very common, 0% - 33% x x x x x x x x x x x x x x x x x x x
Arthralgia 0% - 22% x x x x x x x x x x
Arthralgia Arthralgia 0% - 22% x x x x x x x x x x
Infection Infection 0% - 47% x x x x x x x x x x x x x x x x x x x
Hyperbilirubinaemia Hyperbilirubinaemia 1% - 13% x x x x
Blood creatinine increased Creatinine increased 0% - 31% x x x x x
Hypomagnesaemia Hypomagnesaemia 0% - 17% x x x x x x x x x x x x x x x x
Blood alkaline phosphatase increased Phosphatase alkaline increased 0% - 55% x x x x x
Fatigue Fatigue 0% - 32% x x x x x x x x x x x x x x x x
Diarrhoea Diarrhoea common, 0% - 34% x x x x x x x x x x x x x x x x x x x x
Hypotension Hypotension rare, 0% - 7% x x x x x x x x x x x x x x x x x x
Transaminases increased Transaminases increased 0% - 10% x x x
Transaminitis x
Bronchospasm Allergic bronchospasm 2% x x x x x x x x x x
Bronchospasm uncommon x x x x x x x x x x x x x x x x x x x
Cerebrovascular accident Cerebrovascular accident uncommon x x x x x x x x x x x x x x
Alopecia Alopecia common, 0% - 92% x x x x x x x x x x x x x x x x x x x x
Alopecia reversible x x x x
Haemorrhage Haemorrhage 0% - 23% x x x x x x x x x x x x x x x x x x x x
Haemoglobin Haemorrhage 0% - 23% x x x x x x x x x x x x x x x x x x x x
Hypocalcaemia Hypocalcaemia 0% - 7% x x x x x x x x x x x x x x x
Pain Pain 1% x x x x x x x x x x x x
Paraesthesia Paraesthesia 0% - 26% x x x x x x x x x x x x x x x x x
Pharyngitis Pharyngitis 0% - 13% x x x x x x x x x x x x x x
Stomatitis Stomatitis common, 0% - 66% x x x x x x x x x x x x x x x x x x x x
Generalised oedema Generalised oedema 1% x x x x x x x x x x x x x
Fluid retention Generalised oedema 1% x x x x x x x x x x x x x
Sepsis Sepsis 1% x x x x x x x x x x x x x x x x
Face oedema Face oedema 1% x x x
Somnolence Somnolence common, 0% - 30% x x x x x x x x x x x x x x x x x x x
Arrhythmia Arrhythmia postmarketing, rare x x x x x x x x x x x x x x x x x x x x
Neoplasm malignant Neoplasm malignant postmarketing x x x x x x
Cellulitis Cellulitis postmarketing x x x x x x x x x x x x
Extravasation Extravasation postmarketing x x x x x x x x x x x x x x x x x
Gangrene Gangrene very rare, postmarketing x x x x x x x x x x x x x x x x x
Cardiac failure Cardiac failure postmarketing, rare x x x x x x
Cardiac failure congestive Cardiac failure congestive postmarketing x x x x x x x x x x x x x
Haemolytic uraemic syndrome Haemolytic uraemic syndrome postmarketing — 0.3% x x x x x x x x x x x x x x x x x x x x
Venoocclusive liver disease Venoocclusive liver disease postmarketing x x x x x x x x x
Myocardial infarction Myocardial infarction postmarketing, rare x x x x x x x x x x x x x x x x x x x
Acute coronary syndrome Myocardial infarction postmarketing, rare x x x x x x x x x x x x x x x x x x x
Pulmonary oedema Pulmonary oedema postmarketing, uncommon x x x x x x x x x x x x x x x x x x x x
Pulmonary fibrosis Pulmonary fibrosis postmarketing x x x x x x x x x x x x
Renal failure Renal failure postmarketing, rare x x x x x x x x x
Renal impairment postmarketing x
Progressive renal failure x
Acute respiratory distress syndrome Acute respiratory distress syndrome postmarketing x x x x x x x x x x x x x x x x x
Respiratory distress syndrome x
Angiopathy Angiopathy postmarketing x x x x x x x x x x x x x x x x
Vasculitis Vasculitis very rare, postmarketing x x x x x x x x x x x x x x x x x
Hepatic failure Hepatic failure postmarketing, uncommon x x x x x x x x x x x x x x
Dermatitis bullous Dermatitis bullous very rare, postmarketing x x x x x x x x x x x x x x x x
Injection site reaction Injection site reaction postmarketing, 4% x x x x x x x x x x x x x x x x
Interstitial lung disease Interstitial pneumonia postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Microangiopathic haemolytic anaemia Microangiopathic haemolytic anaemia postmarketing x x x x
Tenderness Tenderness rare x x x
Hepatotoxicity Hepatotoxicity postmarketing, uncommon x x x x x x x x x
Skin exfoliation Skin exfoliation very rare — 0% - 5% x x x x x x x x x x x x x x x x x
Capillary leak syndrome Capillary leak syndrome postmarketing x x x x x x
Arrhythmia supraventricular Arrhythmia supraventricular postmarketing x x x x
Nephropathy toxic Nephropathy toxic postmarketing x x x x
Drug interaction Drug interaction postmarketing x x x x x
Liver function test abnormal Raised liver function tests postmarketing x x x x x x x x x
Respiratory failure Respiratory failure postmarketing x x x x x x x x x x x x
Renal impairment Renal impairment postmarketing x
Recall phenomenon Radiation recall reaction (dermatologic) postmarketing x x x x x x x x x x
Posterior reversible encephalopathy syndrome Posterior reversible encephalopathy syndrome postmarketing x x x x
Toxic epidermal necrolysis Toxic epidermal necrolysis very rare x
Erythema multiforme Stevens-Johnson syndrome very rare x
Stevens-Johnson syndrome Stevens-Johnson syndrome very rare x
Colitis ischaemic Colitis ischaemic very rare x
Thrombocytosis Thrombocytosis very rare x x x
Road traffic accident Traffic accident x x
Agranulocytosis Agranulocytosis x
Decreased appetite Anorexia very common, 0% - 13% x x x x x x x x x x x x x x x x x x x
Bone disorder Bone disorder x
Breast cancer Breast cancer x x x x x x
Chest pain Chest pain x x x
Connective tissue disorder Connective tissue disorder x x x
Cough Cough x x x x x x x x x x x x x x x x x x x x
Dermatitis Rash 0% - 30% x x x x x x x x x x x x x x x x x x x x
Rash Rash 0% - 30% x x x x x x x x x x x x x x x x x x x x
Eruption x x x x x x x x x x x x x
Body temperature increased Body temperature increased common — 0% - 41% x x x x x x x x x x x x x x x x x x x x
Gastrointestinal disorder Gastrointestinal disorder x x x x
Headache Headache very common, 0% - 7% x x x x x x x x x x x x x x x x x x x
Cardiac disorder Cardiac disorder x x x x
Haematuria Haematuria postmarketing — 0% - 35% x x x x x x x x x x x x x x x x x x x x
Hypertension Hypertension x x x x x x x x x x x x x x x x
Hypokalaemia Hypokalaemia x x x x x x x x x
Immune system disorder Immune system disorder x x x x
Influenza Influenza x x x x x x x x x x x x x
Flu symptoms x
Lymphoma Lymphoma x
Non-Hodgkin's lymphoma Lymphoma x
Mediastinal disorder Mediastinal disorder x x
Nervous system disorder Nervous system disorder x x x x
Azoospermia Oligospermia x
Pancytopenia Pancytopenia x x x x x x x x x x x x x
Petechiae Petechiae x x x x x x x x x
Pleural effusion Pleural effusion x x
Pneumonia Pneumonia x
Proteinuria Proteinuria postmarketing — 0% - 45% x x x x x x x x x x x x x x x x x x x x
Protein urine present Proteinuria postmarketing — 0% - 45% x x x x x x x x x x x x x x x x x x x x
Rhinitis Rhinitis x x x x x x x x x x x x x x x x x x x
Hyperhidrosis Sweating x x x x x x x x x x x x x x x x x
Erythema Erythema x
Urethral disorder Urinary tract disorder x x
Urinary tract disorder Urinary tract disorder x x
Hepatic function abnormal Hepatic function abnormal x x x x
Peripheral sensory neuropathy Peripheral sensory neuropathy x
Blood urea increased Blood urea increased 0% - 16% x x x x x
Injection site necrosis Injection site necrosis x x x x x x x x x x x x x
Bone pain Bone pain x x
Streptobacillary fever Streptobacillary fever x x x x x x x x x
Septic arthritis streptobacillus Streptobacillary fever x x x x x x x x x
Skin disorder Unspecified disorder of skin and subcutaneous tissue x x x x
Reticulocytosis Reticulocytosis x x x x x x x x x
Tachypnoea Tachypnoea x
Neuritis Peripheral motor neuropathy x x x x x x x x x x x
Peripheral motor neuropathy Peripheral motor neuropathy x x x x x x x x x x x
Neurotoxicity Neurotoxicity x x x x x x x x x x x x
Poor quality sleep Difficulty sleeping x x
Lung infiltration Lung infiltration x
Hepatic enzyme increased Hepatic enzyme increased x
Hypoxia Hypoxia x x
Hypoxemia x
Disease progression Disease progression x x
Hepatobiliary disease Hepatobiliary disease x x
Traumatic lung injury Traumatic lung injury x
Anaphylactic shock Anaphylactoid reaction x x x x x x x x x x x x x x x x x
Anaphylactoid reaction Anaphylactoid reaction x x x x x x x x x x x x x x x x x
Hyporeflexia Tendon reflex decreased x x x
Blood bilirubin normal Bilirubin normal x
Renal failure chronic Irreversible renal failure x
Cardiotoxicity Cardiotoxicity x x x
Pulmonary toxicity Pulmonary toxicity x x x x x x x x x x x x x x x x x
Oral toxicity Oral toxicity x
Deafness Hearing impaired x x x
Hearing impaired Hearing impaired x x x
Metastatic neoplasm Metastatic disease x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

Gemcitabine

Side effects:46
Source:BC Cancer

GEMCITABINE HYDROCHLORIDE / GEMZAR

Side effects:54
Source:FDA

gemcitabine hydrochloride / GEMZAR

Side effects:67
Source:medicines.org.au

GEMCITABINE HYDROCHLORIDE / GEMZAR

Side effects:76
Source:FDA

GEMCITABINE

Side effects:77
Source:FDA Structured Product Label

gemcitabine

Side effects:77
Source:FDA Structured Product Label

GEMCITABINE

Side effects:79
Source:FDA Structured Product Label

GEMCITABINE

Side effects:79
Source:FDA Structured Product Label

gemcitabine HCl / Gemzar

Side effects:79
Source:FDA

GEMCITABINE

Side effects:81
Source:FDA Structured Product Label

GEMCITABINE

Side effects:83
Source:FDA Structured Product Label

gemcitabine

Side effects:84
Source:FDA Structured Product Label

GEMCITABINE

Side effects:84
Source:FDA Structured Product Label

GEMCITABINE

Side effects:84
Source:FDA Structured Product Label

GEMCITABINE

Side effects:85
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label